All the news Showing 10 of 178 articles from: Hepatitis BGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Core protein inhibitor shows promising activity against hepatitis B Liz Highleyman / 16 April 2019 An experimental hepatitis B virus (HBV) core protein inhibitor led to greater reductions in HBV viral load and residual HBV genetic material when added to nucleoside/nucleotide analogues, which could lead to a functional ... Bulevirtide is a potential cure for hepatitis B and D Liz Highleyman / 16 April 2019 Bulevirtide, formerly known as Myrcludex B, led to suppression of hepatitis delta virus (HDV) and a functional cure of hepatitis B virus (HBV) in some people with both viruses when combined with pegylated ... Global drive for hepatitis B cure launched at International Liver Congress Keith Alcorn / 10 April 2019 The Global Scientific Strategy to Cure Hepatitis B (The ICE-HBV Strategy) by the International Coalition to Eliminate HBV (ICE-HBV), a global group of researchers, patient representatives and health organisations, was released on the opening ... Higher HIV viral load and lower CD4 count linked to liver cancer risk Liz Highleyman / 14 March 2019 People living with HIV who have a longer duration of detectable viral load and those with low CD4 cell counts have a higher likelihood of developing liver cancer in the absence of ... DAA treatment reduces the risk of death and liver cancer in France Keith Alcorn / 12 February 2019 Treatment with direct-acting antivirals (DAAs) reduced the risk of death, liver cancer and death from liver-related causes in French people with hepatitis C, according to results of one of the largest studies ... HIV infection an independent risk factor for poorer survival from liver cancer Michael Carter / 28 January 2019 Infection with HIV is associated with significantly worse survival for people with hepatocellular carcinoma (HCC, the most common type of primary liver cancer), according to findings from a large international cohort study published in ... Lancet commission sets agenda for the elimination of viral hepatitis Keith Alcorn / 10 January 2019 Viral hepatitis leads to around 1.3 million deaths a year, approximately 257 million people are living with hepatitis B virus (HBV) and 71 million with hepatitis C virus (HCV). Viral hepatitis ... Tenofovir alafenamide for hepatitis B shows improved kidney and bone safety after a year Liz Highleyman / 08 January 2019 Tenofovir alafenamide (TAF; Vemlidy), the new formulation of tenofovir, continues to appear at least equally effective for treatment of hepatitis B but with a better safety profile than the older tenofovir disoproxil fumarate ... Hepatitis B capsid assembly modulators show good antiviral activity Liz Highleyman / 21 December 2018 Experimental drugs that interfere with hepatitis B virus (HBV) capsid assembly continue to show promise as a new approach to antiviral treatment, according to research presented at the AASLD Liver Meeting last ... Nivolumab works well for liver cancer patients with advanced disease Liz Highleyman / 26 November 2018 Nivolumab (Opdivo), a checkpoint inhibitor that helps the immune system fight cancer, was associated with tumour shrinkage or disease stabilisation in just over half of hepatocellular carcinoma (HCC) patients with substantial liver function ... ← Prev1...45678...18Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Transmission and prevention Diagnosis and monitoring Disease course and symptoms Treatment HIV and HBV HCV and HBV Hepatitis delta Living with HBV Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds